备注请放最后面 违者新闻文章删除
1.媒体来源:
外媒
marketwatch
2.记者署名:
By Tomi Kilgore
3.完整新闻标题:
Eli Lilly to supply the U.S. government with doses of COVID-19 treatment
etesevimab for $330 million
4.完整新闻内文:
Eli Lilly to supply the U.S. government with doses of COVID-19 treatment
etesevimab for $330 million
Published: Sept. 15, 2021 at 6:53 a.m. ET
By Tomi Kilgore
Eli Lilly & Co. LLY, -2.05% announced Wednesday to sell 388,000 doses of
etesevimab, which has been authorized for emergency use as a COVID-19
treatment for $330 million. As part of the deal, about 200,000 doses of
etesevimab, which complements doses of bamlanivimab previously purchased by
the U.S. government, are expected to ship in the third quarter of 2021, with
the remaining doses to be shipped in the fourth quarter. "The recent increase
in COVID-19 cases has caused a substantial rise in the utilization of
monoclonal antibody drugs, particularly in areas of the country with low
vaccination rates," said Lilly's Chief Scientific and Medical Officer Daniel
Skovronsky. "Lilly developed bamlanivimab and etesevimab for administration
together, in anticipation of variants such as the highly contagious Delta
variant, which currently accounts for more than 98 percent of all identified
COVID-19 cases in the U.S." Eli Lilly's stock, which was still inactive in
premarket trading, has run up 38.1% year to date, while the S&P 500 SPX,
-0.57% has gained 18.3%.
Eli Lilly & Co. LLY, -2.05% 周三宣布以 3.3 亿美元的价格出售 388,000 剂
etesevimab，该药已被授权紧急用作 COVID-19 治疗。作为交易的一部分，约 200,000
剂 etesevimab 补充美国政府先前购买的 bamlanivimab 剂量，预计将于 2021 年第三季
度发货，其余剂量将在第四季度发货。
“最近 COVID-19 病例的增加导致单基因复制抗体药物的使用大幅增加，特别是在该国
疫苗接种率低的地区，”礼来公司的首席科学和医学官 Daniel Skovronsky 说。
“礼来开发了 bamlanivimab 和 etesevimab 用于联合给药，预防出现变异，
例如高传染性的 Delta 变异， 斯必克， -0.57% 上涨了 18.3%。
5.完整新闻连结 (或短网址):
https://is.gd/XdoJ72
6.备注:
以色列打到第七针后终于看到尽头了呢！顺带一提Etesevimab的药源是中国，看来解铃
还需系铃人，药头总是最了解自己手上的货呢！
https://imgur.com/jJxylCV
Etesevimab（LY-CoV016，又名JS016）最初由君实生物与中国科学院微生物所共同开发，
去年礼来从君实生物获得授权，主导大中华地区以外全球地区的临床开发。这两款抗体均
靶向刺突蛋白受体结合域（RBD），但是靶向RBD的不同表位，因此组合疗法可能产生更好
的治疗效果。